Evidence of significant synergism between antibiotics and the antipsychotic, antimicrobial drug flupenthixol

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 31, Issue 6, 2012, Pages 1243-1250

  Jeyaseeli, L ^a   Dasgupta, A ^a,e   Dastidar, S G ^b   Molnar, J ^c   Amaral, L ^d  

^a JADAVPUR UNIVERSITY   (India)

^b Herbicure Healthcare Bio Herbal Research Foundation   (India)

^c UNIVERSITY OF SZEGED   (Hungary)

^d UNIVERSIDADE NOVA DE LISBOA   (Portugal)

^e NATIONAL INSTITUTE ON AGING   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; ANTIBIOTIC AGENT; CHLORAMPHENICOL; CIPROFLOXACIN; ERYTHROMYCIN; FLUPENTIXOL; GENTAMICIN; METHDILAZINE; NEUROLEPTIC AGENT; PENICILLIN G; PROMETHAZINE; STREPTOMYCIN; TETRACYCLINE; TRIFLUPROMAZINE; ANTIINFECTIVE AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; CONTROLLED STUDY; DISK DIFFUSION; DRUG EFFECT; DRUG POTENTIATION; DRUG SCREENING; IN VIVO STUDY; INFECTION PREVENTION; MALE; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; TYPHOID FEVER; ANIMAL; ANIMAL SALMONELLOSIS; BACTERIUM; DISEASE MODEL; HUMAN; MICROBIOLOGICAL EXAMINATION; TREATMENT OUTCOME;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTIPSYCHOTIC AGENTS; BACTERIA; DISEASE MODELS, ANIMAL; DRUG SYNERGISM; FLUPENTHIXOL; HUMANS; MALE; MICE; MICROBIAL SENSITIVITY TESTS; SALMONELLA INFECTIONS, ANIMAL; TREATMENT OUTCOME;

EID: 84863851418     PISSN: 09349723     EISSN: 14354373     Source Type: Journal    
DOI: 10.1007/s10096-011-1435-3     Document Type: Article

References (64)

1. Pagès JM, Amaral L, Fanning S (2011) An original deal for new molecule: reversal of efflux pump activity, a rational strategy to combat gram-negative resistant bacteria. Curr Med Chem 18:2969-2680
2. Machado L, Spengler G, Evaristo M, Handzlik J, Molnár J, Viveiros M, Kiec-Kononowicz K, Amaral L (2011) Biological activity of twenty three hydantoin derivatives on intrinsic efflux pump system of Salmonella enterica Enteritidis NCTC 13349. In Vivo 25:769-772
3. Takács D, Cerca P, Riedl Z, Hajós G, Molnár J, Viveiros M, Couto I, Amaral L (2011) Evaluation of forty new phenothiazine derivatives for activity against intrinsic efflux pump systems of reference Escherichia coli, Salmonella Enteritidis, Enterococcus faecalis and Staphylococcus aureus strains. In Vivo 25:719-724
4. Dasgupta A, Dastidar SG, Shiratki Y, Motohashi N (2004) Antibacterial activity of artificial phenothiazines and isoflavones from plants. In: Bioactive heterocycles, VI, vol 15. Springer, Berlin Heidelberg, pp 67-132
5. Dasgupta A, Jeyaseeli L, Dutta NK, Mazumdar K, Karak P, Dastidar SG, Motohashi N, Shirataki Y (2007) Studies on the antimicrobial potential of the cardiovascular drug lacidipine. In Vivo 21:847-850 (Pubitemid 350019808)
6. Levy SB, Marshall B (2004) Antibacterial resistance worldwide: cause, challenges and responses. Nat Med 10 [Suppl]:S122-S129 (Pubitemid 40018235)
7. Martinez JL, Baquero F, Anderson DI (2007) Predicting antibiotic resistance. Nat Rev Microbiol 5:958-965 (Pubitemid 350138975)
8. Bhatawadekar S, Chattopadhyay A (2010) Quinpristin-dalfopristin resistance among methicillin-resistant strains of Staphylococcus. Indian J Pharmacol 42:56
9. Howe RA, Monk F, Wootton M, Wlash TR, Enright MC (2004) Vancomycin susceptibility within methicillin resistant Staphylococcus aureus lineages. Emerg Infect Dis 10:855-857 (Pubitemid 38552753)
10. Dastidar SG, Chaudhury A, Annadurai S, Roy S, Mookerjee M, Chakrabarty AN (1995) In vitro and in vivo antimicrobial action of fluphenazine. J Chemother 7:201-206
11. Dastidar SG, Debnath S, Mazumdar K, Ganguly K, Chakrabarty AN (2004) Triflupromazine: a microbicide non-antibiotic compound. Acta Microbiol Immun Hung 51:75-83 (Pubitemid 39178440)
12. Jeyaseeli L, Dasgupta A, Kumar KA, Mazumdar K, Dutta NK, Dastidar SG (2006) Antimicrobial potentiality of thioxanthene fluphenthixol through extensive in vitro and in vivo experiments. Int J Antimicrob Agents 27:58-62 (Pubitemid 43042424)
13. Kristiansen JE (1992) The antimicrobial activity of nonantibiotics. APMIS 100:7-14
14. Mazumdar R, Ganguly K, Dastidar SG, Chakrabarty AN (2001) Trifluoperazine: a broad-spectrum bactericide especially active on staphylococci and vibrios. Int J Antimicrob Agents 18:403-406 (Pubitemid 33016358)
15. Keyzer H, Eckert GM, Forrest IS, Gupta RR, Gutmann F, Molnar J (eds) (1992) Thiazines and structurally related compounds. Krieger, Malabar, pp 197-202
16. Annadurai S, Guhathakurta A, Sa B, Dastidar SG, Ray R, Chakrabarty AN (2002) Experimental studies on synergism between aminoglycosides and the antimicrobial anti-inflammatory agent diclofenac sodium. J Chemother 14:47-53 (Pubitemid 34259171)
17. Asok Kumar K, Mazumdar K, Dutta NK, Karak P, Dastidar SG, Ray R (2004) Evaluation of synergism between the aminoglycoside antibiotic streptomycin and the cardiovascular agent amlodipine. Biol Pharm Bull 27:1116-1120 (Pubitemid 41701770)
18. Basu LR, Mazumdar K, Dutta NK, Karak P, Dastidar SG (2005) Antibacterial property of the antipsychotic agent prochlorperazine, and its synergism with methdilazine. Microbiol Res 160:95-100 (Pubitemid 40199408)
19. Dasgupta A, Chaki S, Mukherjee S, Jeyaseeli L, Mazumdar K, Dutta NK, Dastidar SG (2010) Experimental analyses of synergistic combinations of antibiotics with a recently recognized antibacterial agent, lacidipine. Eur J Clin Microbiol Infect Dis 29:239-243
20. Amaral L, Kristiansen JE, Lorian V (1992) Synergistic effect of chlorpromazine on the activity of some antibiotics. J Antimicrob Chemother 30:556-558
21. Kristiansen JE, Amaral L (1997) The potential management of resistant infections with non-antibiotics. J Antimicrobial Chemother 40:319-327 (Pubitemid 27437949)
22. Collee FG, Miles RS, Watt B (1996) Mackie & McCartney's practical medical microbiology, 14th edn. Churchill Livingstone, New York, pp 131-150
23. McFarland J (1907) Nephelometer: an instrument for estimating the number of bacteria in suspensions. J Am Med Assoc 14:1176- 1178
24. Clinical and Laboratory Standards Institute (2009) Methods for dilution antimicrobial susceptibility testing of bacteria that grow aerobically, 7th edn. Approved standard M7-A7.2009. Clinical and Laboratory Standards Institute, Wayne, PA
25. Clinical and Laboratory Standards Institute (2009) Performance Standards for antimicrobial disk susceptibility tests, 10th edn. Approved standard M02-A10.2009. Clinical and Laboratory Standards Institute, Wayne, PA
26. Miles RS, Amyes SGB (1996) Laboratory control of antimicrobial therapy. In: Collee JG, Fraser AG, Marmino BP, Simons A (eds) Mackie & McCartney's practical medical microbiology. Churchill Livingstone, New York, pp 151-177
27. Eliopoulos GM, Moellering RC Jr (1996) Antimicrobial combinations. In: Lorian V (ed) Antibiotics in laboratory medicine, 4th edn. Williams & Wilkins, Baltimore, MD, pp 432-492
28. American Society for Microbiology (1995) Instruction to authors. Antimicrob Agents Chemother 39:i-xiv
29. Mitruka BM, Rawnsle HM, Vadehra DV (eds) (1976) In: Animals for medical research. Wiley, New York, pp 145-150
30. Dasgupta A, Mukherjee S, Chaki S, Dastidar SG, Hendricks O, Christensen JB, Kristiansen JE, Amaral L (2010) Thioridazine protects the mouse from a virulent infection by Salmonella enterica Serovar Typhimurium 74. Int J Antimicrob Agents 35:174-176
31. Mishra L (ed) (2006) Drugs today; ready reckoner of current medical formulations. Lorina, New Delhi
32. Crossland J (1980) Lewis's pharmacology. Churchill Livingstone, London. pp 834-835
33. Mazumdar K, Dutta NK, Kumar KA, Dastidar SG (2005) An in vitro and in vivo synergism between tetracycline and the cardiovascular agent oxyfedrine HCl against common bacterial strains. Biol Pharm Bull 28:713-717 (Pubitemid 40879943)
34. Amaral L, Fanning S, Pagès JM (2011) Efflux pumps of gramnegative bacteria: genetic responses to stress and the modulation of their activity by pH, inhibitors, and phenothiazines. Adv Enzymol Relat Areas Mol Biol 77:61-108
35. Rodrigues L, Aínsa JA, Amaral L, Viveiros M (2011) Inhibition of drug efflux in mycobacteria with phenothiazines and other putative efflux inhibitors. Recent Pat Antiinfect Drug Discov 6:118-127
36. Jin J, Zhang JY, Guo N, Sheng H, Li L, Liang JC, Wang XL, Li Y, Liu MY, Wu XP, Yu L (2010) Farnesol, a potential efflux pump inhibitor in Mycobacterium smegmatis. Molecules 15:7750-7762
37. Kristiansen JE, Thomsen VF, Martins A, Viveiros M, Amaral L (2010) Non-antibiotics reverse resistance of bacteria to antibiotics. In Vivo 24:751-754
38. Amaral L, Martins A, Molnar J, Kristiansen JE, Martins M, Viveiros M, Rodrigues L, Spengler G, Couto I, Ramos J, Dastidar S, Fanning S, McCusker M, Pages JM (2010) Phenothiazines, bacterial efflux pumps and targeting the macrophage for enhanced killing of intracellular XDRTB. In Vivo 24:409-424
39. Dutta NK, Mehra S, Kaushal D (2010) A Mycobacterium tuberculosis sigma factor network responds to cell-envelope damage by the promising anti-mycobacterial thioridazine. PLoS One 5:e10069
40. Rodrigues L, Sampaio D, Couto I,Machado D, KernWV, Amaral L, Viveiros M (2009) The role of efflux pumps in macrolide resistance inMycobacterium avium complex. Int J Antimicrob Agents 34:529- 533
41. Spengler G, Martins A, Schelz Z, Rodrigues L, Aagaard L, Martins M, Costa SS, Couto I, Viveiros M, Fanning S, Kristiansen JE, Molnar J, Amaral L (2009) Characterization of intrinsic efflux activity of Enterococcus faecalis ATCC29212 by a semiautomated ethidium bromide method. In Vivo 23:81-87
42. Kvist M, Hancock V, Klemm P (2008) Inactivation of efflux pumps abolishes bacterial biofilm formation. Appl Environ Microbiol 74:7376-7382 (Pubitemid 352773583)
43. Sabatini S, Kaatz GW, Rossolini GM, Brandini D, Fravolini A (2008) From phenothiazine to 3-phenyl-1,4-benzothiazine derivatives as inhibitors of the Staphylococcus aureus NorA multidrug efflux pump. J Med Chem 51:4321-4330 (Pubitemid 352032457)
44. Couto I, Costa SS, Viveiros M, Martins M, Amaral L (2008) Efflux-mediated response of Staphylococcus aureus exposed to ethidium bromide. J Antimicrob Chemother 62:504-513
45. Tegos GP, Masago K, Aziz F, Higginbotham A, Stermitz FR, Hamblin MR (2008) Inhibitors of bacterial multidrug efflux pumps potentiate antimicrobial photoinactivation. Antimicrob Agents Chemother 52:3202-3209
46. Lehtinen J, Lilius EM (2007) Promethazine renders Escherichia coli susceptible to penicillin G: real-time measurement of bacterial susceptibility by fluoro-luminometry. Int J Antimicrob Agents 30:44-51 (Pubitemid 46874903)
47. Kristiansen JE, Hendricks O, Delvin T, Butterworth TS, Aagaard L, Christensen JB, Flores VC, Keyzer H (2007) Reversal of resistance in microorganisms by help of non-antibiotics. J Antimicrob Chemother 59:1271-1279 (Pubitemid 47073346)
48. Chan YY, Ong YM, Chua KL (2007) Synergistic interaction between phenothiazines and antimicrobial agents against Burkholderia pseudomallei. Antimicrob Agents Chemother 51:623- 630
49. Kristiansen MM, Leandro C, Ordway D, Martins M, Viveiros M, Pacheco T, Molnar J, Kristiansen JE, Amaral L (2006) Thioridazine reduces resistance of methicillin-resistant staphylococcus aureus by inhibiting a reserpine-sensitive efflux pump. In Vivo 20:361-366 (Pubitemid 43772670)
50. Ramón-García S, Martín C, Aínsa JA, De Rossi E (2006) Characterization of tetracycline resistance mediated by the efflux pump Tap from Mycobacterium fortuitum. J Antimicrob Chemother 57:252-259 (Pubitemid 43160166)
51. Marquez B (2005) Bacterial efflux systems and efflux pumps inhibitors. Biochimie 87:1137-1147 (Pubitemid 41572643)
52. Amaral L, Viveiros M, Molnar J (2004) Antimicrobial activity of phenothiazines. In Vivo 18:725-731. Review
53. Hendricks O, Butterworth TS, Kristiansen JE (2003) The in-vitro antimicrobial effect of non-antibiotics and putative inhibitors of efflux pumps on Pseudomonas aeruginosa and Staphylococcus aureus. Int J Antimicrob Agents 22:262-264 (Pubitemid 37103210)
54. Gunn JS (2008) The Salmonella PmrAB regulon: lipopolysaccharide modifications, antimicrobial peptide resistance and more. Trends Microbiol 16:284-290
55. Moreau A, Le Vee M, Jouan E, Parmentier Y, Fardel O (2011) Drug transporter expression in human macrophages. Fundam Clin Pharmacol. doi:0.1111/j.1472-8206.2010.00913.x
56. Lemaire S, Tulkens PM, Van Bambeke F (2010) Cellular pharmacokinetics of the novel biaryloxazolidinone radezolid in phagocytic cells: studies with macrophages and polymorphonuclear neutrophils. Antimicrob Agents Chemother 54:2540-2548
57. Lemaire S, Kosowska-Shick K, Appelbaum PC, Verween G, Tulkens PM, Van Bambeke F (2010) Cellular pharmacodynamics of the novel biaryloxazolidinone radezolid: studies with infected phagocytic and nonphagocytic cells, using Staphylococcus aureus, Staphylococcus epidermidis, Listeria monocytogenes, and Legionella pneumophila. Antimicrob Agents Chemother 54:2549-2559
58. Baudoux P, Lemaire S, Denis O, Tulkens PM, Van Bambeke F, Glupczynski Y (2010) Activity of quinupristin/dalfopristin against extracellular and intracellular Staphylococcus aureus with various resistance phenotypes. J Antimicrob Chemother 65:1228-1236
59. Kodavanti UP, Lockard VG, Mehendale HM (1990) In vivo toxicity and pulmonary effects of promazine and chlorpromazine in rats. J Biochem Toxicol 5:245-251
60. Dijkstra J, van Galen M, Scherphof G (1985) Effects of (dihydro) cytochalasin B, colchicine, monensin and trifluoperazine on uptake and processing of liposomes by Kupffer cells in culture. Biochim Biophys Acta 845:34-42 (Pubitemid 15083872)
61. Drenckhahn D, Kleine L, Lüllmann-Rauch R (1976) Lysosomal alterations in cultured macrophages exposed to anorexigenic and psychotropic drugs. Lab Invest 35:116-123
62. Molnár J, Haszon I, Bodrogi T, Martonyi E, Turi S (1990) Synergistic effect of promethazine with gentamycin in frequently recurring pyelonephritis. Int Urol Nephrol 22:405-411
63. Amaral L, Viveiros M, Molnar J, Kristiansen JE (2011) Effective therapy with the neuroleptic thioridazine as an adjunct to second line of defence drugs, and the potential that thioridazine offers for new patents that cover a variety of "New Uses". Recent Pat Antiinfect Drug Discov 6:84-87
64. Amaral L, Boeree MJ, Gillespie SH, Udwadia ZF, van Soolingen D (2010) Thioridazine cures extensively drug-resistant tuberculosis (XDR-TB) and the need for global trials is now! Int J Antimicrob Agents 35:524-526